{"id":"W4403565766","doi":"10.1093/oncolo/oyae237","title":"Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer","year":2024,"lang":"en","type":"review","venue":"The Oncologist","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Oncology; Adverse effect; Population; Cancer; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01430555,0.001048574,0.00713096,0.004386829,0.0003216478,0.002230018,0.001068312,0.001633832,0.003684741],"category_scores_gemma":[0.03120664,0.0005690739,0.01271279,0.002832999,0.0007272315,0.001287898,0.0008647058,0.001354062,0.000270231],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00242654,"about_ca_system_score_gemma":0.002671662,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002571166,"about_ca_topic_score_gemma":0.006138086,"domain_scores_codex":[0.9870753,0.007795274,0.002887329,0.000765709,0.001282812,0.0001935727],"domain_scores_gemma":[0.9810271,0.01190402,0.005296856,0.0003450079,0.001145667,0.0002812793],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.04329073,0.0003770198,0.003168837,0.5815243,0.2882102,0.0001137186,0.0001902505,0.0007410215,0.0009113457,0.0006703426,0.0008242627,0.07997806],"study_design_scores_gemma":[0.03707649,0.01621404,0.01531119,0.1288822,0.7896701,0.0003560375,0.0003170047,0.0008902496,0.0009501634,0.001417645,0.008797957,0.0001170459],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.02188684,0.9741583,0.0003947964,0.0004031603,0.0002462321,0.0008854155,0.000746939,0.00001640825,0.001261971],"genre_scores_gemma":[0.4425917,0.5497122,0.002651902,0.001298131,0.0004449155,0.001791196,0.001021602,0.0000207676,0.0004675022],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01430555,"threshold_uncertainty_score":0.07565588,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2252177205887461,"score_gpt":0.4877370934272039,"score_spread":0.2625193728384578,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}